Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model

Molecular Cancer Therapeutics

Volumn 3, Issue 8, 2004, Pages 977-983

  Raben, David ^a   Bianco, Cataldo ^b   Damiano, Vincenzo ^c   Bianco, Roberto ^c   Melisi, Davide ^c   Mignogna, Chiara ^c   D'Armiento, Francesco Paolo ^c   Cionini, Luca ^b   Bianco, A Raffaele ^c   Tortora, Giampaolo ^c   Ciardiello, Fortunato ^d   Bunn, Paul ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; MONOCLONAL ANTIBODY KI 67; N ACETYLCOLCHINOL PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL LOSS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; THROMBOSIS; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 4444280232     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting-agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
2. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53:164-71.
3. Su Hang HJ, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-35.
4. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-7.
5. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
6. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effects and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), and epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
7. Sirotnak F, Zakowski M, Miller V, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
8. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in on-small cell lung cancer. Semin Oncol 2002;29:37-46.
9. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3250-8.
10. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62:4300-6.
11. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999;10:2493-506.
12. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5: 2884-90.
13. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Gullinane C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003; 55:713-23.
14. Thomlinson J. Tumor anoxia and the response to radiation. Sci Basis Med Annu Rev 1965;74-90.
15. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract]. Proc Am Soc Clin Oncol 2000;19:484A.
16. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
17. Kris M, Natale RB, Herbst R, et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21:292a, abstract 1166.
18. Fukuoka K, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
19. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ("Iressa," ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. 2nd ed. Proc Am Assoc Cancer Res 2003:44.
20. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vitro: a role for altered tumor angiogenesis. Cancer Res 2001;61: 5090-101.
21. Chakravarti A, Loefler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
22. Ciardiello F, Caputo R, Bianco R, et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 1998;90: 1087-94.
23. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
24. Normanno N, Campiglio M, De LA, et al. Cooperative inhibitory effect of ZD1 839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13:65-72.
25. Baker CH, Solorzano CC, Fidler U. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002 Apr 1; 62:1996-2003.